Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina

References

• Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640–1642.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 2016;15:385–403.
   PubMed Web of Science ®Google Scholar
• D’Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 2007;171:14–18.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLOS One 2008;3:e3554.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943–954.
   PubMed Web of Science ®Google Scholar
• Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19:5731–5740.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53–67.
   PubMed Web of Science ®Google Scholar
• Zinkernagel MS, Schorno P, Ebneter A, et al. Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant. Invest Ophthalmol Vis Sci 2015;56:1894–1900.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Shapiro H, Tuomi, L et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118:523–530.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398.
   PubMed Web of Science ®Google Scholar
• Yang K, Cepko CL. Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. J Neurosci 1996;16:6089–6099.
   PubMed Web of Science ®Google Scholar
• Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40:2115–2121.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Vranes D, Berka JL, et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998;78:1017–1027.
   PubMed Web of Science ®Google Scholar
• Tokunaga CC, Mitton KP, Dailey W, et al. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2014;55:1884–1892.
   PubMed Web of Science ®Google Scholar
• Froger N, Matonti F, Roubeix C, et al. VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci Rep 2020;10:12409.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Westenskow PD, Bravo S, et al. Targeted deletion of Vegf a in adult mice induces vision loss. J Clin Invest 2012;122:4213–4217.
   PubMed Web of Science ®Google Scholar
• Romano MR, Biagioni F, Besozzi G, et al. Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res 2012;1478:55–63.
   PubMed Web of Science ®Google Scholar
• Cheng CK, Peng PH, Tien LT, et al. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina 2009;29:306–312.
   PubMed Web of Science ®Google Scholar
• Inan UU, Baysal Z, Inan S. Long-term changes in retinal layers in patients undergoing intravitreal ranibizumab for neovascular age-related macular degeneration: retinal layers after anti-VEGF therapy. Int Ophthalmol 2019;39:2721–2730.
   PubMed Web of Science ®Google Scholar
• Beck M, Munk MR, Ebneter A, et al. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 2016;167:10–17.
   PubMed Web of Science ®Google Scholar
• Kim SY, Yoon MH, Chin HS. Changes in the ganglion cell-inner plexiform layer after consecutive intravitreal injections of anti-vascular endothelial growth factor in age-related macular degeneration patients. Korean J Ophthalmol 2020;34:11–18.
   PubMedGoogle Scholar
• Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 2012;53:6214–6218.
   PubMed Web of Science ®Google Scholar
• Horsley MB, Mandava N, Maycotte MA, et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2010;150:558–561.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Machida S, Harada T, et al. Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol 2012;6:1073–1082.
   PubMedGoogle Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179–2182.
   PubMed Web of Science ®Google Scholar
• Velez-Montoya R, Fromow-Guerra J, Burgos O, et al. The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 2009;29:20–26.
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 2017;37:1847–1858.
   PubMed Web of Science ®Google Scholar
• Nieves-Moreno M, Martínez-de-la-Casa JM, Morales-Fernández L, et al. Impacts of age and sex on retinal layer thicknesses measured by spectral-domain optical coherence tomography with Spectralis. PLoS One 2018;13:e0194169.
   PubMed Web of Science ®Google Scholar